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Duchenne muscular dystrophy
Quality of life among 95 patients evaluated using 
the Life Satisfaction Index for Adolescents
Valdecir A. Simon1, Maria Bernardete Dutra Resende1, 
Margarete A.V.P. Simon2, Edmar Zanoteli1,3, Umbertina Conti Reed1
ABSTRACT
The purpose of this study was to evaluate the quality of life (QoL) of patients with 
Duchenne muscular dystrophy (DMD) in different stages of the disease, by means of the 
Life Satisfaction Index for Adolescents (LSI-A). The practicality of this scale was also verified. 
The LSI-A was applied four times to 95 patients with DMD who were undergoing steroid 
therapy, at three-month intervals. The patients were divided into four groups according to 
age. The results from the four applications and the inter and intra-examiner concordance 
were treated statistically. Comparing the different age groups, patients with DMD did not 
lose QoL, even with disease progression. We concluded that, in spite of the progressive 
course of the disease, the QoL in patients with DMD does not get worse. The use of a 
scale that embraces a great diversity of circumstances in patients’ lives, without considering 
clinical aspects excessively, is a good alternative for assessing the QoL of these patients. 
Key words: quality of life, Duchenne muscular dystrophy, steroid therapy, questionnaire, 
Life Satisfaction Index for Adolescents.
Distrofia muscular de Duchenne: avaliação da qualidade de vida em 95 pacientes 
através do Life Satisfaction Index for Adolescents
RESUMO
O objetivo deste estudo foi de quantificar a qualidade de vida (QV) em crianças com 
distrofia muscular de Duchenne (DMD) em diferentes idades através do uso do questionário 
Life Satisfaction Index for Adolescents (LSI-A). Foi também avaliada a praticidade do 
questionário. O LSI-A foi aplicado a 95 pacientes com distrofia muscular de Duchenne em 
corticoterapia, em diferentes idades, e por quatro vezes com intervalos de três meses. Os 
resultados concernentes às quatro avaliações e a concordância inter e intra-observador 
foram tratados estatisticamente. Comparando diferentes faixas etárias, mesmo ao longo 
da progressão da doença, não notamos perda da QV. Concluímos que por não valorizar 
excessivamente os aspectos clínicos e abranger uma diversidade de circunstâncias 
cotidianas, O LSI-A é útil na avaliação da QV das crianças com DMD, sendo também de 
fácil aplicação. 
Palavras-chave: qualidade de vida, distrofia muscular de Duchenne, corticoterapia, 
questionário, Life Satisfaction Index for Adolescents.
Correspondence
Valdecir A. Simon
Av. Dr. Eneas de Carvalho 
Aguiar, 255 / sala 5083
05403-000 São Paulo SP - Brasil
E-mail: valdecirsimon@usp.br
Received 18 January 2010
Received in final form 13 August 2010
Accepted 20 August 2010
1Department of Neurology, School of Medicine, University of São Paulo, São Paulo SP, Brazil; 2University São Judas Tadeu, 
São Paulo SP, Brazil; 3Assistance Association for Handicapped Children (AACD), São Paulo SP, Brazil.
Duchenne muscular dystrophy (DMD) 
is a degenerative disease with sex-linked 
recessive inheritance caused by mutations 
in the dystrophin gene in Xp211,2. The dis-
ease shows high prevalence and incidence 
and affects one in 3,600 to 6,000 liveborn 
males3,4. DMD has a progressive and irre-
versible clinical course that initially is pre-
dominantly in the proximal limb-girdle 
muscles5. The symmetrical and progres-
sive decline in muscle strength and mo-
tor skills over the course of time was well 
established by Scott et al.6, and the annual 
decline in muscle strength is around 2%7. 
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The main causes of death are cardiac muscle impairment, 
occurring in 70% of the patients, and restrictive respira-
tory failure8,9.
Among patients with DMD, steroid therapy delays 
the loss of muscle strength and respiratory capacity10-12. 
Steroid therapy improves muscle strength within two to 
four months after beginning the treatment, and it helps 
to maintain independent walking for at least two more 
years13. In addition, steroid therapy has a positive and sig-
nificant impact on quality of life (QoL) and on the cost/
benefit relationship of medical care14,15. In addition to ste-
roid therapy, non-invasive mechanical ventilation meth-
ods are important palliative approaches involving QoL16. 
In short, respiratory and heart support in association with 
steroid therapy currently enables survival beyond 30 years 
of age. with the patient maintaining good QoL17.
QoL assessments relate more to subjective issues, 
such as negative and positive aspects of perceptions and 
individual expectations of life, than to objective issues, 
i.e. environmental and social variables. Good assessment 
methods need to be multidimensional and to reflect cul-
tural influences18. QoL questionnaires19 should not only 
detect changes in QoL over the course of evolution of 
the disease, but also help to predict future disability and 
the prognosis20.
The Life Satisfaction Index for Adolescents (LSI-A) 
questionnaire was developed by Reid and Renwick21 in 
1994 and was validated in a study on 15 adolescents with 
DMD. It evaluates five domains relating to satisfaction 
with life: general wellbeing, interpersonal relationships, 
personal development, personal satisfaction and leisure 
and recreation. It includes a total of 45 items and can be 
either self-administered or applied by family members 
or multidisciplinary staff. This questionnaire has mini-
mal interference with motor function and clinical issues, 
and thus it seems to be a very effective means for DMD 
patients to assess their QoL. Given the scarcity of studies 
on QoL relating to DMD, we applied the LSI-A to a large 
group of patients with DMD, of different ages, in order to 
find out whether the progression of the disease affects pa-
tients’ QoL and, in addition, to investigate the practicality 
and effectiveness of this questionnaire for DMD patients. 
METHOD
We evaluated 95 patients with DMD, aged 5 to 17 
years, who had been undergoing steroid therapy with 
prednisolone (intermittent use of 0.75 mg/kg/day, oral-
ly, in alternating periods of 10 days on/off) or deflazacort 
(continuous use of 0.9 mg/kg/day, orally) and were being 
followed up at the Outpatient Clinic for Neuromuscular 
Diseases at our Institution. The diagnosis of DMD was 
made by molecular testing or immunohistochemistry/
Western blotting of dystrophin in muscle biopsy samples. 
After obtaining prior authorization from the authors21, 
the Life Satisfaction Index for Adolescents questionnaire 
was applied to all patients between May 2007 and Octo-
ber 2008. In order to ensure greater accuracy and preci-
sion for the data obtained from the questionnaire, it was 
applied on four different occasions with three-month in-
tervals between the applications. The patients were di-
vided into four groups according to age: Group A (n=11), 
from five to seven years of age; group B (n=40), from eight 
to 10 years; group C (n=28), from 11 to 13 years; and 
group D (n=16), from 13 to 17 years of age. The question-
naire was adapted verbally so that it would be understood 
by children under 12 years of age. The only interventions 
made were in relation to the definitions of some words, 
when necessary. Because of the need to understand the 
questionnaire, patients with mental retardation were ex-
cluded. The patients’ parents signed a consent form in ac-
cordance with the approval granted by the Ethics Com-
mittee of our Institution. The statistical methodology was 
based on Rosner22. The agreement between pairs of ex-
aminers (inter-observer reliability) and the agreement be-
tween the observations made by the same examiner on 
different occasions (intra-observer reliability and test-re-
test) were evaluated using the Bland-Altman graphical 
method. Intra and inter-observer measurements were 
made on 31% of patients, and their values were found to 
be concentrated between –1 and +1. The Kruskal-Wal-
lis test was used for comparisons between the groups at 
each application and, when the comparison was signifi-
cant, the Dunn test was applied. The Friedman test al-
lowed us to compare different moments of the evaluation 
in each group. To compare the average of the four eval-
uations between the four groups in all five domains, we 
used one-way ANOVA. For all statistical measurements, 
the significance level of p<0.05 was used. 
RESULTS
Among the 95 patients, 39 were wheelchair users, and 
two of the latter had motorized chairs. Concerning edu-
cation levels, eight patients had not attended any school, 
three had reached high school level (two had profession-
al occupations) and 82 had completed elementary school. 
The patients were always accompanied by their caregivers 
when they came to the hospital for appointments. Nine-
ty-two patients were accompanied by their parents; two 
were under the care of grandparents and one was under 
the tutelage of his stepfather. 
In the General Wellbeing domain, the mean score 
showed a statistically significant increase (p<0.05) only 
in group B (8-10 years of age), therefore signifying an in-
crease in QoL over the nine months of follow-up. The 
domains of Personal Development, Personal Satisfaction, 
Leisure and Recreation and Interpersonal Relationship 
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showed statistically significant increases over the course 
of the four evaluations in all groups (p<0.05). These re-
sults indicated that over this period of evaluation, the pa-
tients were able to cope with the disease without demon-
strating anxiety, were satisfied with their lives, had active 
participation in cultural life and maintained good affec-
tive and social contact with friends and relatives.
Comparing the averages of the four evaluations be-
tween the four groups in all the five domains, there was 
no statistically significant difference (one-way ANOVA; 
p>0.05) (Table). We considered this result to be satisfac-
tory, because it indicated that there was no loss of QoL 
among the older children who were more affected be-
cause of the progressive course of the disease.
DISCUSSION
In this study, we observed that there was no signif-
icant difference in QoL comparisons between different 
age groups of patients with DMD, despite the progres-
sive course of the disease. In facing up to this disease, 
determination of the subjective aspects of QoL is essen-
tial for the clinical evaluation and complements it. Spe-
cific instruments that can accurately depict patients’ in-
terpretations of the disease are required. Although sev-
eral QoL questionnaires can be applied to evaluate pa-
tients with serious chronic diseases, there are few stud-
ies relating to DMD. However, it is clear that systematic 
application of QoL questionnaires to patients with DMD 
who are highly disabled and aware of their prognosis, is 
extremely valuable for adequate multidisciplinary thera-
peutic planning and for better support for patients and 
their families. 
It is important to evaluate QoL not only through care-
givers’ opinions but also through patients’ perspectives, 
because the parents may have a negative perception about 
their child. To analyze this issue, Gonçalves et al.23 applied 
the questionnaire Autoquestionnaire Qualité de Vie En-
fant Imagé (AUQUEI). This has already been validated in 
Brazil24 and is composed of 26 questions that assess fam-
ily relationships, social activities, health and body func-
tions. Among 18 DMD patients and their 18 caregivers, 
they did not observe any statistical difference between 
the scores obtained through the perceptions of children 
and caregivers. The mothers and their children shared 
the same opinions, and the children’s QoL was consid-
ered satisfactory. 
Melo et al.25 applied AUQUEI to 14 children with 
DMD and found that they had good QoL. They also noted 
that there was agreement between the children and their 
caregivers. The most representative domains that they 
assessed were function, family and leisure. Interesting-
ly, the children gave more importance to obtaining bet-
ter mobility using their wheelchairs than using support-
ed gait. The practicality of the AUQUEI questionnaire is 
relevant but, because evaluating QoL is a complex mat-
ter, we believe that this questionnaire is deficient with 
regard to the diversity of circumstances surrounding life 
and human QoL. 
Another questionnaire that can be applied to these 
patients is the Medical Outcomes Study 36-item Short-
Form (SF-36)26,27. This is divided into eight domains and 
covers physical and functional characteristics. However, 
the SF-36 clearly correlates the progressive decline due to 
DMD with a decline in QoL. Activities of daily living are 
not the only parameters for assessing QoL, and this is of-
ten unrelated to the physical disability28. Given that pa-
tients’ survival has now increased considerably, in spite 
of the unavoidable progression of the motor and respira-
tory dysfunction, we believe that the SF-36 is inappropri-
ate for assessing the QoL of DMD patients because it em-
phasizes the clinical aspects of the disease. 
The LSI-A questionnaire seems to be adequate for 
DMD patients, since its five domains cover a great diver-
sity of daily circumstances. The questions correlate to a 
lesser degree with the clinical findings, and therefore en-
able a more accurate quantification of patients’ QoL. Al-
though this questionnaire was recommended for patients 
over 12 years of age, we found in our study that the it was 
also applicable to younger children, although requiring 
cultural adjustment.
In conclusion, our QoL assessment using LSI-A among 
95 patients with DMD showed that there was no lose of 
Table. Representation of the scores obtained in the LSI-A domains.
Group N
General 
Wellbeing [A]
Interpersonal 
Relationship [B]
Personal 
Development [C]
Personal 
Satisfaction [D]
Leisure and 
Recreation [E]
A – 11 28.5±3.665 33.625±3.462 35.125±2.992 33.125±1.83 34.375±2.857
B – 40 28.25±3.267 34.212±2.927 35.265±2.712 33±2.007 33.875±3.375
C – 28 28.06±2.722 34.25±3.562 35.25±3.877 32.937±3.235 33.312±3.48
D – 16 29.625±3.272 35.9±3.595 36.06±4.53 33.5±2.57 34.625±3.037
[A] General Wellbeing, [B] Interpersonal Relationship, [C] Personal Development, [D] Personal Satisfaction and [E] Leisure and Recreation, over the follow-
up period in the four groups of patients with DMD. The comparisons between the four groups did not show any significant differences (one-way ANOVA, 
p>0.05). N: number of patients.
Arq Neuropsiquiatr 2011;69(1)
22
QL: Duchenne dystrophy
Simon et al.
QoL, even among the older children who were more af-
fected by the diseases, probably because this scale covers 
a wide variety of daily circumstances and does not give 
excessive value to the clinical aspects. According to Bray 
et al.29, QoL is independent of clinical aspects. The ques-
tionnaire accurately expressed QoL and met the require-
ments for QoL assessment among children with DMD.
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